The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@aol.com; or J. Aubrey Waddell, Director, Oncology Pharmacy Residency Program, Department of Pharmacy, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, Rm 2P02, Washington, D.C.; E-mail: waddfour@charter.net.
Get full access to this article
View all access options for this article.
References
1.
JemalA., MurrayT., WardW.E.. Cancer statistics. 2005. CA Cancer J Clin.2005; 55(1): 10–30.
2.
ShawJ.C.Overview of melanoma. Up to date. Available at: http://www.uptodate.com/. Accessed on November 14, 2005.
3.
SeiglerH.F., LucasV.S., PickettN.J., HuangA.T.DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer.1980; 46(11): 2346–2348.
4.
YorkR.M., FoltzA.T.Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer.1988; 61(11): 2183–2186.
5.
Prudente Foundation Melanoma Study Group.Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). Cancer.1989; 63(9): 1676–1680.
6.
LakhaniS., SelbyP., BlissJ.M., PerrenT.J., GoreM.E., McElwainT.J.Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer.1990; 61(2): 330–334.
7.
PyrhonenS., Hahka-KemppinenM., MuhonenT.A promising Interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol.1992; 10(12): 1919–1926.
8.
MuhonenT., Hahka-KemppinenM., PakkalaS., PyrhonenS.Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma. J Immunother.1994; 15(1): 67–73.
9.
Hahka-KemppinenM., MuhonenT., VirolainenM., JekunenA., Asko-SeljavaaraS., PyrhonenS.Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. Br J Dermatol.1995; 132(6): 973–977.
10.
PuntC.J., van HerpenC.M., JansenR.L., VreugdenhilG., MullerE.W., de MulderP.H.Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alfa for metastatic melanoma: a multicentre phase II study. Br J Cancer.1997; 76(2): 266–269.
11.
PyrhonenS., Hahka-KemppinenM., MuhonenT.. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer.2002; 95(11): 2366–2372.
12.
KivelaT., SuciuS., HanssonJ.. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer.2003; 39(8): 1115–1120.
13.
VuoristoM., GrohnP., KumpulainenE., KorpelaM.Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon alfa. Eur J Cancer.1994; 30A(3): 420.
14.
VuoristoM.S., GrohnP., Kellokumpu-LehtinenP.. Intermittent interferon and polychemotherapy in metastatic melanoma. J Cancer Res Clin Oncol.1995; 121(3): 175–180.
15.
NathanF., BerdD., ShieldsJ.A.. BOLD+Interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Cancer Res.1997; 16(2): 201–208.
16.
ReinholdU., BruskeT., KreyselH.W.Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon-alpha for metastatic melanoma. Eur J Cancer.1996; 32A(1): 180.
17.
National Comprehensive Cancer Network. NCCN melanoma practice guideline. Version 2.2005. Available at: http://www.nccn.org/. Accessed on November 14, 2005.
18.
TrisselL., ZhangY., CohenM.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36(7): 740–745.
National Comprehensive Cancer Network. NCCN antiemesis practice guidelines. Available at: http://www.nccn.org/. Accessed on November 14, 2005.
21.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
22.
Multinational Association for Supportive Care in Cancer. Antiemetic Guidelines. 2005. Available: at http://www.mascc.org/. Accessed on December 22, 2005.
23.
GelingO., EichlerH.G.Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
24.
GrallaR.G., OsobaD., KrisM.G.. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17(9): 2971–2994.
LymanG.H.Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol.2003; 30(Suppl 13): 10–17.
29.
OzerH., ArmitageJ.O., BennettC.L.. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18(20): 3558–3585.
30.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
31.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–405.
32.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
33.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
34.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. PerryM.C., ed. In: The Chemotherapy Sourcebook.3rd ed.Philadelphia, PA: Lippincott Williams and Wilkins; 2001; 494–504.
35.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6(2): 162–176.
